Time-restricted Eating in Patients With Moderate Chronic Kidney Disease and Albuminuria
NCT ID: NCT06618859
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2024-12-04
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The precise pathophysiology of CKD is not fully understood, but recent research highlights metabolic alterations, particularly in lipid and glucose metabolism. CKD progression is influenced by diet, as evidenced by recent studies. Interventions such as the ketogenic diet and time-restricted feeding show promising results in improving metabolism and may have beneficial effects on CKD.
Our study aims to evaluate the impact of time-restricted eating (TRE) on proteinuria, the decline in glomerular filtration rate, and weight loss in patients with moderate CKD with albuminuria (KDIGO stage 2-3). This will allow us to better understand the efficacy of this dietary approach tailored to the individual habits of participants.
The primary outcome measure will be albuminuria before and after the 12-week intervention. Secondary outcome measures will include the impact of fasting on blood pressure as assessed by 24-hour ambulatory monitoring, body composition evaluated by DXA and BIA, continuous glucose monitoring, and blood hormone profiles. Additionally, the feasibility and safety of TRE in this population will be assessed.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Time-restricted eating
Time-restricted eating
Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.
Active control
Active control
Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Time-restricted eating
Participants will be advised to consume meals and calorie-containing drinks only during a window of 8 hours, to be self-selected by the participant and advised by the investigators based on their daily routine and eating habits during the run-in phase.
Active control
Participants will be advised to keep the same eating rhythm and timing of meals per day during the intervention.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult men and women
* Chronic Kidney Disease with KDIGO stage G2 and G3 defined by a Glomerular Filtration Rate between 30 and 90 mL/min/1.73m2
* Albuminuria stage A2 or A3, but without nephrotic-range proteinuria: 3 to 200 mg/mmol
* Body mass index 18-40 kg/m2
* Eating window of 12 hours (self-reported and measured during the run-in phase)
* Study-related criteria
* Able to give informed consent and follow the study procedures for the entire duration
* Confident use of a smartphone compatible with the MyFoodRepo app (iOS, Android) and able to take regular pictures of food/drinks
Exclusion Criteria
* Pregnant and breastfeeding women, plans for maternity during the study
* Eating disorder(s)
* Other diets: low-carb, ketogenic diet, hypocaloric diets (eviction for food intolerances, vegan/vegetarian diet are not excluded)
* Uncontrolled blood pressure (\> 160/100 mmHg)
* Diabetes with hypoglycemic drug(s) will be excluded, however those with impaired glucose tolerance (prediabetes, as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included
* Oral corticosteroids
* Uncontrolled diabetes HbA1c \> 8.5%
* Active cancer and/or oncologic treatment over the previous 12 months
* Major mental illness
* Consumption of \> 7 standard units of alcohol per week for women and \> 14 standard units of alcohol per week for men
* Shift work, such as evening shifts or night shifts planned during the study
* Travel/trip to a different time zone (≥ 2-hour time difference) planned during the study
* Study-related criteria and other interventions
* Recent treatment modification in the last 3 months, including but not limited to ACE blockers, SLGT2i, finerenone
* Patients with recent glomerulonephritis diagnosis on more than 2 immunosuppressive drugs
* Patients with kidney transplant in the last past year
* Enrolled in another interventional clinical trial (medication, medical device) over the previous 1 month and planned during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Geneva
OTHER
de Seigneux Sophie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
de Seigneux Sophie
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sophie de Seigneux, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Geneva
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital, Geneva
Geneva, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sophie de Seigneux, MD, PhD
Role: primary
Anna Faivre, MD, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-02172
Identifier Type: -
Identifier Source: org_study_id